5ROCHE-LESTIENNE C, LEPERS S, SOENENCORNU V, et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics [J]. Leukemia, 2005,19 : 792- 798.
6VANDENBERGHE P,WLODARSKA I, MICHAUX L, et al. Clinical and molecular features of FIP1L1-PD FGRA (+) chronic eosinophilic leukemias[J]. Leukemia,2004,18: 734-742.
7JOVANOVIC J V, SCORE J, WAGHORN K, et al. Low-dose imatinih mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-posi rive chronic eosinophilic leukemia[J].Blood, 2007, 109:4635-4640.
8COOLS J,DEANGELO D J, GOTLIB J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinphilie syndrome[J]. N Engl J Med, 2003,384: 1201-1214.
9CHUSID M J,DALE D C,WEST B C,et al. The hypereosinophilic syndrome: Analysis of fourteen cases with review of the literature[J].Medicine, 1975,54 : 1 -27.
5Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy [ J ]. J Pharmacol Exp Ther,2005,315 ( 3 ) :971-979.
6Breccia-M, Efficace F, Alimena GI Imatinib treatment in chronic myelogenous leukemia:what have we learned so far? [ J 3. Cancer Lett,2011,300(2) :115-121.
7Frolov A, Chahwan S, Ochs M, et al. Response markers and them olecularm echanisms of action of Gleevec in gastrointestinal stromal tumors [ J ]. Mol Cancer Ther,2003,2 ( 8 ) :699-709.
9Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative [J]. Cancer Res, 1996, 56(1): 100-104.
10Druker B J, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J]. Nat Med, 1996, 2(5): 561-566.
